Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response criteria and availability of novel effective therapies. However, previous studies have focused on newly diagnosed patients, and little is known on relapsed patients, despite the fact that trials of new agents are often performed in this setting. In the present study, we report the outcome of 259 patients who responded to up-front therapy. Ninety-two patients (35%) needed second-line therapy after a median of 49 months. Cardiac and renal progression were observed in 22% and 12% of patients who received second-line therapy, respectively. Complete response after upfront treatment and frontline therapy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-line therapy. Median survival of relapsing patients was 59 months. Patients who had a “high-risk dFLC progression,” which we defined as a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of baseline value, and a >50% increase from the value reached at best response, had a shorter survival after initiation of second-line therapy on univariate, but not on multivariate, analysis, where cardiac progression was the only independent predictor of survival after starting rescue treatment. Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome. A “high-risk dFLC progression” should trigger rescue treatment, and cardiac progression should not be awaited.

Original languageEnglish
Pages (from-to)525-532
Number of pages8
JournalBlood
Volume131
Issue number5
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Amyloidosis
Melphalan
Biomarkers
Dexamethasone
Availability
Therapeutics
Survival
Light
Multivariate Analysis
Bortezomib
Kidney

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

@article{20b6fbd218c4498eb1595598d0c35c6c,
title = "Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies",
abstract = "The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response criteria and availability of novel effective therapies. However, previous studies have focused on newly diagnosed patients, and little is known on relapsed patients, despite the fact that trials of new agents are often performed in this setting. In the present study, we report the outcome of 259 patients who responded to up-front therapy. Ninety-two patients (35{\%}) needed second-line therapy after a median of 49 months. Cardiac and renal progression were observed in 22{\%} and 12{\%} of patients who received second-line therapy, respectively. Complete response after upfront treatment and frontline therapy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-line therapy. Median survival of relapsing patients was 59 months. Patients who had a “high-risk dFLC progression,” which we defined as a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20{\%} of baseline value, and a >50{\%} increase from the value reached at best response, had a shorter survival after initiation of second-line therapy on univariate, but not on multivariate, analysis, where cardiac progression was the only independent predictor of survival after starting rescue treatment. Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome. A “high-risk dFLC progression” should trigger rescue treatment, and cardiac progression should not be awaited.",
author = "Giovanni Palladini and Paolo Milani and Andrea Foli and Marco Basset and Francesca Russo and Stefano Perlini and Giampaolo Merlini",
year = "2018",
month = "2",
day = "1",
doi = "10.1182/blood-2017-04-780544",
language = "English",
volume = "131",
pages = "525--532",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

AU - Palladini, Giovanni

AU - Milani, Paolo

AU - Foli, Andrea

AU - Basset, Marco

AU - Russo, Francesca

AU - Perlini, Stefano

AU - Merlini, Giampaolo

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response criteria and availability of novel effective therapies. However, previous studies have focused on newly diagnosed patients, and little is known on relapsed patients, despite the fact that trials of new agents are often performed in this setting. In the present study, we report the outcome of 259 patients who responded to up-front therapy. Ninety-two patients (35%) needed second-line therapy after a median of 49 months. Cardiac and renal progression were observed in 22% and 12% of patients who received second-line therapy, respectively. Complete response after upfront treatment and frontline therapy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-line therapy. Median survival of relapsing patients was 59 months. Patients who had a “high-risk dFLC progression,” which we defined as a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of baseline value, and a >50% increase from the value reached at best response, had a shorter survival after initiation of second-line therapy on univariate, but not on multivariate, analysis, where cardiac progression was the only independent predictor of survival after starting rescue treatment. Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome. A “high-risk dFLC progression” should trigger rescue treatment, and cardiac progression should not be awaited.

AB - The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response criteria and availability of novel effective therapies. However, previous studies have focused on newly diagnosed patients, and little is known on relapsed patients, despite the fact that trials of new agents are often performed in this setting. In the present study, we report the outcome of 259 patients who responded to up-front therapy. Ninety-two patients (35%) needed second-line therapy after a median of 49 months. Cardiac and renal progression were observed in 22% and 12% of patients who received second-line therapy, respectively. Complete response after upfront treatment and frontline therapy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-line therapy. Median survival of relapsing patients was 59 months. Patients who had a “high-risk dFLC progression,” which we defined as a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of baseline value, and a >50% increase from the value reached at best response, had a shorter survival after initiation of second-line therapy on univariate, but not on multivariate, analysis, where cardiac progression was the only independent predictor of survival after starting rescue treatment. Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome. A “high-risk dFLC progression” should trigger rescue treatment, and cardiac progression should not be awaited.

UR - http://www.scopus.com/inward/record.url?scp=85041351640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041351640&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-04-780544

DO - 10.1182/blood-2017-04-780544

M3 - Article

AN - SCOPUS:85041351640

VL - 131

SP - 525

EP - 532

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -